and AUD diagnosis [3]. The enrichments in regulatory regions point to specific brain tissues relevant to the causative genes; the specific interactions between 16 genes and 325 drugs may provide targets for the development of medications to manage PAU. Potential targets identified include the D2 dopamine receptor (encoded by DRD2) and phosphodiesterase 4B (encoded by PDE4B). The presence of risk variation at these loci also suggests that they may be “precision medicine” targets as well.
